This evidence-based guideline offers practical recommendations for this difficult-to-manage disease.
Sponsoring Organizations: American Society of Hematology, International Society on Thrombosis and Haemostasis, National Hemophilia Foundation, and World Federation of Hemophilia Background and Objective
Von Willebrand disease (vWD) is a common inherited bleeding tendency often characterized by easy bruising, epistaxis, heavy menstrual bleeding, and bleeding after dental and other procedures and surgeries. Given variability in management of the disease, a multidisciplinary panel developed evidence-based guidelines.
Key Recommendations
When desmopressin is considered as a future treatment option (typically for type 1 vWD), a baseline trial is suggested to confirm efficacy, especially in patients with von Willebrand factor (vWF) levels <0.30 IU/…
Reviewing Author
DisclosuresLeadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)
DisclosuresLeadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)